Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587395 | 0.81 | CA1 (0.31) | CA1 | |
| SCHEMBL13100466 | 0.81 | KDM4E (0.39) | SMN1; SMN2CA1CA12CA2CA14 | |
| SCHEMBL26323259 | 0.78 | CA1 (0.55) | SMN1; SMN2CA1RAB9ACA12CA2 | |
| SCHEMBL6224352 | 0.77 | LMNA (0.34) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL11949255 | 0.75 | CNR1 (0.34) | HTTALDH1A1POLB | |
| SCHEMBL13301125 | 0.74 | — | — | |
| SCHEMBL12256296 | 0.74 | LMNA (0.33) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL6012003 | 0.74 | LMNA (0.33) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL26870697 | 0.74 | VCAM1 (0.32) | — | |
| SCHEMBL6224354 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAHTTCA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210137910-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-13 | — | — | US | disclosed |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-06-04 | — | — | US | disclosed |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSIT (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3124482-B1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-09-11 | — | — | EP | disclosed |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-10363248-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-30 | — | — | US | disclosed |
| US-20090297537-A1 | Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-7326729-B2 | CXCR1 and CXCR2 chemokine antagonists | SCHERING CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070248594-A1 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | SCHERING CORPORATION | 2007-10-25 | — | — | US | disclosed |
| US-20070248594-A1 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | SCHERING CORPORATION | 2007-10-25 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | SMN1; SMN2 3741/4885LMNA 4785/4885HTT 3554/4885 |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SMN1; SMN2 3911/4885LMNA 4082/4885HTT 2755/4885 |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | IDO1, IDO2, MMP1 | SMN1; SMN2 1391/4885LMNA 1162/4885HTT 1881/4885 |
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | SMN1; SMN2 3273/4885LMNA 3698/4885HTT 492/4885 |
| US-10363248-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, VHL, HIF1A | SMN1; SMN2 3273/4885LMNA 3698/4885HTT 492/4885 |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | SMN1; SMN2 4811/4885LMNA 2463/4885HTT 4501/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | SMN1; SMN2 3882/4885LMNA 4541/4885HTT 3263/4885 |
| US-20070248594-A1 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | CXCR1, CXCR2, CXCR5 | SMN1; SMN2 4668/4885LMNA 4869/4885HTT 4457/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | SMN1; SMN2 3741/4885LMNA 4785/4885HTT 3554/4885 |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, VHL, HIF1A | SMN1; SMN2 3273/4885LMNA 3698/4885HTT 492/4885 |
| US-20210137910-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | SMN1; SMN2 3273/4885LMNA 3698/4885HTT 492/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SMN1; SMN2 3911/4885LMNA 4082/4885HTT 2755/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | SMN1; SMN2 3741/4885LMNA 4785/4885HTT 3554/4885 |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | JAK3, JAK1, JAK2 | SMN1; SMN2 3741/4885LMNA 4785/4885HTT 3554/4885 |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | SMN1; SMN2 4669/4885LMNA 3878/4885HTT 1594/4885 |
| US-20090297537-A1 | Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, DPP4, GIPR | SMN1; SMN2 4555/4885LMNA 3718/4885HTT 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.